UPDATE - Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses
MWN-AI** Summary
Visionary Holdings Inc. (NASDAQ: GV) announced a significant move into the high-margin medical aesthetics market, highlighted by a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in partnership with Huajin China Investment Company. This agreement sets a minimum sales target of US$12 million within a 12-month period and marks a crucial step in commercializing the product, reflecting its growing acceptance in the market and enhancing revenue visibility.
In conjunction with this agreement, Visionary Holdings is strategically refocusing its operations by divesting from non-core businesses. The company recently completed the transfer of 100% equity in Visionary Education Services & Management Inc. to Cai Dao Trading Ltd., a decision aimed at optimizing its business structure and capital efficiency. The divestiture allows Visionary Holdings to concentrate on high-margin injectable products, regenerative medical aesthetics, and biotechnology-driven healthcare innovations.
CEO Xiyong Hou emphasized that these changes position the company for a focused growth phase in the medical aesthetics market, following extensive strategic evaluations to identify high-value directions. The exclusive deal for the Premier Regenerative Complex signifies a new growth cycle characterized by operational focus and improved financial flexibility.
Huajin China, the partner for the distribution agreement, operates an extensive network of health and wellness centers across China, facilitating a strong entry point for Visionary Holdings’ products. As the company gears up to expand its footprint in the aesthetic and wellness sectors, it aims to leverage its streamlined operations and increased resources to support sustainable expansion. Overall, these strategic decisions reflect Visionary Holdings’ commitment to advancing within the burgeoning medical aesthetics industry.
MWN-AI** Analysis
Visionary Holdings Inc. (NASDAQ: GV) has recently made strategic moves that signal a pivotal shift towards high-margin medical aesthetics. The exclusive distribution agreement with Huajin China Investment Company for its flagship product, Premier Regenerative Complex-President Super Injection, marks a significant commercialization milestone. The projected US$12 million sales target within a year, coupled with the divestiture of its non-core business, indicates a focused approach towards maximizing revenue and operational efficiency.
This shift is well-timed given the growing consumer demand for anti-aging and regenerative aesthetics. With the aesthetics market projected to continue its robust growth, Visionary's emphasis on high-tech healthcare solutions could position it favorably against competitors. The divestiture of non-core assets enhances capital efficiency, allowing management to allocate resources to high-margin segments that can yield robust returns.
Investors should note that while these developments provide optimism about short- to medium-term revenue growth, they also come with inherent risks. The company's success hinges on the effective execution of this strategy, particularly in delivering on sales targets and market acceptance of the Premier Regenerative Complex. The risk of dependence on a single product and market fluctuations in aesthetics cannot be underestimated.
Long-term prospects appear encouraging, especially with management indicating a scalable business model focused on sustainable growth. Those considering an investment in Visionary Holdings should watch key performance indicators, including sales activity in the coming quarters and overall market dynamics in the medical aesthetics landscape. Establishing a position in GV now could be beneficial as it transitions into this focused growth phase, but prudent risk management and ongoing analysis will be essential for navigating potential volatility in stock performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company?”Huajin China”), alongside the Board-approved divestiture of its non-core business.
These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.
Commercialization Milestone for Premier Regenerative Complex – President Super Injection
The Company’s wholly owned subsidiary, Visionary Health Technology Group Limited, has entered into an exclusive distribution agreement with Huajin China, establishing a minimum contracted sales target of US$12 million within a 12-month period. Revenue recognition will be subject to product delivery, customer acceptance, and applicable accounting standards.
This agreement represents a significant step in scaling the commercial deployment of Premier Regenerative Complex – President Super Injection, reflecting growing market acceptance and strengthening revenue visibility.
Strategic Divestiture to Concentrate on Core Medical Aesthetics Track
On February 27, 2026, the Company’s Board of Directors approved the transfer of 100% equity interests in Visionary Education Services & Management Inc. to Cai Dao Trading Ltd., completing the planned exit from non-core legacy business operations. In addition, in light of the Company’s evolving business development needs, the Board also approved a change in the Company’s transfer agent service provider.
Following this divestiture, Visionary Holdings will operate as a streamlined biotechnology and healthcare-focused enterprise, allocating capital, technology and management resources exclusively toward:
- Anti-aging injectable products
- Regenerative medical aesthetics
- Biotechnology-driven healthcare innovation
The product is intended for aesthetic and wellness applications and is not intended to diagnose, treat, cure, or prevent any disease.
Management Commentary
Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
“With the completion of our core business refocusing and asset structure optimization, the Company is formally entering a more focused and execution-driven growth phase within the global medical aesthetics market.
Over the past several years, we have undertaken extensive strategic evaluation and operational refinement to identify the most scalable and value-accretive direction for Visionary Holdings. Through disciplined analysis and market validation, we have established medical aesthetics and regenerative injectable products as our long-term core growth engine.
The signing of this exclusive distribution agreement for Premier Regenerative Complex – President Super Injection™ represents not only a significant commercialization milestone, but also the beginning of a new execution-centered growth cycle. At the same time, the divestiture of our non-core assets materially enhances our capital efficiency and strengthens our financial flexibility.
By concentrating resources on high-margin, high-growth medical aesthetics and biotechnology-driven healthcare innovation, we believe the Company is entering a structured growth cycle characterized by improved revenue visibility, stronger operational focus, and enhanced financial capacity to support sustainable expansion.”
About Huajin China Investment Company
Huajin China is an industry-focused operating platform dedicated to community-based smart elderly care and senior health management. The Company has established more than 900 health and wellness chain centers across over 20 provinces in China, forming an integrated “offline service network + digital management system + health product supply chain” operating model. Leveraging a light-asset franchise structure and standardized replication capabilities, Huajin has strategically expanded into China’s county-level elderly care markets while advancing the digital transformation of smart home-based senior care services. Looking ahead, the Company aims to drive industry consolidation and capital market integration to become a leading AI-driven digital elderly care platform in the Asia-Pacific region.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Contacts:
Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings
FAQ**
How does the exclusive distribution agreement with Huajin China benefit Goldfield Corporation (The) GV in terms of market penetration and revenue generation for the Premier Regenerative Complex?
What measures is Goldfield Corporation (The) GV implementing to ensure successful execution of the minimum contracted sales target of US$12 million within the next 12 months?
In what ways could the divestiture of non-core assets enhance Goldfield Corporation (The) GV's financial flexibility and operational focus in the medical aesthetics sector?
How does Goldfield Corporation (The) GV plan to leverage its technology-driven approach in high-tech healthcare solutions to compete in the rapidly growing global medical aesthetics market?
**MWN-AI FAQ is based on asking OpenAI questions about Goldfield Corporation (The) (NASDAQ: GV).
NASDAQ: GV
GV Trading
-12.17% G/L:
$0.628 Last:
252,987 Volume:
$0.7146 Open:
